Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKETEER: RXC008 in Crohn's Disease Strictures
NCT07832435Phase 2Not yet recruiting
- Sponsor
- Redx Pharma
- Start
- Oct 2026
- Primary completion
- Aug 2028
01
Overview
Phase 2, randomised, double-blind trial of RXC008 in Crohn's disease (3 arms), sponsored by Redx Pharma. Primary endpoint: Absolute change from baseline in primary stricture at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RXC008
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07832435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832435.